| Financier | Commitments |
|---|---|
| IDA Credit | 41.30 |
| IDA Grant | 454.30 |
Ethiopia COVID-19 Emergency Response
Abstract*
This document presents a Global MPA Program as a response to COVID-19, and includes two countries: Islamic Republic of Afghanistan, and Democratic Republic of Ethiopia. Other countries will join the program as they are ready. Show More
Development Objective
To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Ethiopia.
Key Details
Project Details
P173750
Active
Roman Tesfaye , Tseganeh Guracha
Federal Democratic Republic of Ethiopia
March 27, 2020
(as of board presentation)
April 2, 2020
April 14, 2020
US$ 495.60 million
Ministry of Health
2020
US$ 495.60 million
N/A
March 26, 2024
December 31, 2025
No
BANK APPROVED
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | N/A |
| IDA Commitment | 495.60 |
| IBRD + IDA Commitment | 495.60 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | 495.60 |
Summary Status of World Bank Financing (US$ Millions) as of February 28, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| Jun 11, 2020 | IDA-65870 | Loan Disb | 769,783.94 |
| Aug 19, 2020 | IDA-65870 | Loan Disb | 111,104.28 |
| Oct 23, 2020 | IDA-65870 | Loan Disb | 108,702.89 |
| Nov 1, 2021 | IDA-65870 | Loan Disb | 872,383.25 |
| Nov 3, 2021 | IDA-65870 | Loan Disb | 427,657.75 |
| Jun 28, 2021 | IDA-65870 | Loan Disb | 17,659,466.00 |
| Oct 15, 2021 | IDA-65870 | Int Charges | 193.96 |
| Oct 15, 2021 | IDA-65870 | Int Charges | 193.96 |
| Oct 15, 2021 | IDA-65870 | Int Charges | 90,070.77 |
| Oct 15, 2021 | IDA-65870 | Int Charges | 90,070.77 |
| Apr 16, 2021 | IDA-65870 | Int Charges | 467.30 |
| Apr 16, 2021 | IDA-65870 | Int Charges | 467.30 |
| Apr 16, 2021 | IDA-65870 | Int Charges | 47,148.83 |
| Apr 16, 2021 | IDA-65870 | Int Charges | 47,148.83 |
| Jul 15, 2021 | IDA-65870 | Loan Disb | -25,815.26 |
| Apr 9, 2021 | IDA-65870 | Loan Disb | 1,282,973.20 |
| Dec 21, 2020 | IDA-65870 | Loan Disb | 167,851.61 |
| Dec 20, 2021 | IDA-D9550 | Loan Commitment | 206,000,000.00 |
| Mar 26, 2021 | IDA-D7910 | Loan Commitment | 207,000,000.00 |
| May 31, 2022 | IDA-E0640 | Loan Commitment | 195,000,000.00 |
| Dec 4, 2023 | IDA-D9550 | Loan Cancel | 73,960,256.00 |
| Dec 4, 2023 | IDA-D7910 | Loan Cancel | 42,739,916.00 |
| Jun 17, 2024 | IDA-D7910 | Loan Disb | 9,130,484.00 |
| Jun 11, 2024 | IDA-D9550 | Loan Disb | 3,140,000.00 |
| Apr 2, 2020 | IDA-65870 | Loan Commitment | 41,300,000.00 |
| Apr 2, 2020 | IDA-D5940 | Loan Commitment | 41,300,000.00 |
| Mar 15, 2023 | IDA-D7910 | Loan Disb | -220,260.78 |
| Aug 1, 2023 | IDA-D9550 | Loan Disb | 3,033,210.00 |
| Aug 23, 2023 | IDA-E0640 | Loan Disb | 12,735,000.00 |
| Jan 26, 2023 | IDA-E0640 | Loan Disb | 2,963,022.00 |
| Sep 1, 2023 | IDA-E0640 | Loan Disb | 487,400.00 |
| Sep 1, 2023 | IDA-D9550 | Loan Disb | 22,650,000.00 |
| Dec 21, 2023 | IDA-E0640 | Loan Disb | 1,500,000.00 |
| Nov 1, 2023 | IDA-D7910 | Loan Disb | 615,021.10 |
| Mar 8, 2024 | IDA-E0640 | Loan Disb | 17,281,432.00 |
| Apr 3, 2024 | IDA-D9550 | Loan Disb | 113,568.00 |
| Sep 22, 2022 | IDA-65870 | Loan Disb | 7,370,609.50 |
| Oct 15, 2022 | IDA-65870 | Int Charges | 2,956.08 |
| Oct 15, 2022 | IDA-65870 | Int Charges | 2,956.08 |
| Oct 15, 2022 | IDA-65870 | Int Charges | 110,816.33 |
| Oct 15, 2022 | IDA-65870 | Int Charges | 110,816.33 |
| Aug 14, 2020 | IDA-65870 | Loan Disb | 5,680,000.00 |
| Jun 18, 2020 | IDA-65870 | Loan Disb | 3,468,190.00 |
| May 3, 2022 | IDA-D7910 | Loan Disb | 32,756,782.00 |
| May 31, 2022 | IDA-D7910 | Loan Disb | 15,272,712.00 |
| Sep 27, 2021 | IDA-D7910 | Loan Disb | 4,500,000.00 |
| Dec 19, 2022 | IDA-E0640 | Loan Disb | 58,370,576.00 |
| Dec 23, 2021 | IDA-D7910 | Loan Disb | 253,911.00 |
| Feb 2, 2022 | IDA-D7910 | Loan Disb | 924,978.90 |
| Feb 2, 2022 | IDA-D7910 | Loan Disb | 4,408,992.00 |
| Jan 21, 2022 | IDA-D7910 | Loan Disb | 1,189,338.00 |
| Oct 6, 2022 | IDA-D9550 | Loan Disb | 37,537,092.00 |
| Nov 30, 2022 | IDA-E0640 | Loan Disb | 2,992,549.80 |
| Sep 23, 2022 | IDA-D7910 | Loan Disb | 38,385,172.00 |
| Jan 27, 2023 | IDA-D9550 | Loan Disb | 9,152,759.00 |
| Sep 22, 2021 | IDA-D7910 | Loan Disb | 1,368,479.80 |
| Oct 27, 2021 | IDA-D7910 | Loan Disb | 1,102,248.00 |
| Jun 28, 2021 | IDA-D7910 | Loan Disb | 22,720,828.00 |
| Jun 30, 2021 | IDA-D5940 | Loan Disb | 112,938.81 |
| Jun 23, 2020 | IDA-D5940 | Loan Disb | 41,750,368.00 |
| Dec 16, 2021 | IDA-D7910 | Loan Disb | 855,341.75 |
| Apr 15, 2024 | IDA-65870 | Int Charges | 2,242.94 |
| Apr 15, 2024 | IDA-65870 | Int Charges | 2,242.94 |
| Apr 15, 2024 | IDA-65870 | Int Charges | 139,719.80 |
| Apr 15, 2024 | IDA-65870 | Int Charges | 139,719.80 |
| Apr 15, 2023 | IDA-65870 | Int Charges | 291.62 |
| Apr 15, 2023 | IDA-65870 | Int Charges | 291.62 |
| Apr 28, 2023 | IDA-65870 | Int Charges | 143,936.94 |
| Apr 28, 2023 | IDA-65870 | Int Charges | 143,936.94 |
| Oct 30, 2023 | IDA-65870 | Int Charges | 141,459.11 |
| Oct 30, 2023 | IDA-65870 | Int Charges | 141,459.11 |
| Oct 30, 2023 | IDA-65870 | Int Charges | 1,012.89 |
| Oct 30, 2023 | IDA-65870 | Int Charges | 1,012.89 |
| Oct 9, 2020 | IDA-65870 | Loan Disb | 2,036,397.80 |
| Oct 20, 2020 | IDA-65870 | Int Charges | 17,873.18 |
| Oct 20, 2020 | IDA-65870 | Int Charges | 17,873.18 |
| Apr 15, 2022 | IDA-65870 | Loan Disb | 85,531.54 |
| Apr 15, 2022 | IDA-65870 | Int Charges | 116,740.82 |
| Apr 15, 2022 | IDA-65870 | Int Charges | 116,740.82 |
| Apr 15, 2022 | IDA-65870 | Int Charges | 541.50 |
| Apr 15, 2022 | IDA-65870 | Int Charges | 541.50 |
Ratings
IMPLEMENTATION RATINGS
| Name | Review | Date |
|---|---|---|
| Procurement | Moderately Satisfactory | 2024-11-25 |
| Project Management | Moderately Satisfactory | 2024-11-25 |
| Financial Management | Moderately Unsatisfactory | 2024-11-25 |
| Progress towards achievement of PDO | Moderately Satisfactory | 2024-11-25 |
| Monitoring and Evaluation | Moderately Satisfactory | 2024-11-25 |
| Overall Implementation Progress (IP) | Moderately Satisfactory | 2024-11-25 |
COMPLETION RATINGS
No data available.
INDEPENDENT EVALUATION RATINGS
No data available.
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Achieving the required timeliness of reporting for COVID-19 and other immediately reportable diseases under IDSR Value 0.00 84.50 80.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Percentage of priority population vaccinated, which is included in the priority population targets defined in national plan by gender Value 0.00 75.80 70.00 Date January 14, 2021 April 2, 2024 December 31, 2025 Comment Percentage of grievances addressed within the time specified in the project implementation manual Value 0.00 88.24 80.00 Date December 3, 2021 April 2, 2024 December 31, 2025 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Number of health workers, health facility facilities Surveillance focal persons, PoE screeners, and Woreda, Zonal and regional PHEMofficers trained on COVID-19. Value 88.00 19879.00 2457.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Assessment conducted to identify behavioral and socio-cultural risk factors for COVID-19 covering all the regions. Value No Yes Yes Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Number of health extension workers received orientation to strength COVID-19 community-based surveillance Value 0.00 35222.00 27600.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Key COVID19 vaccine messages disseminated through various media outlets (radio, TV, social media, print media etc) Value 0.00 2594936.00 20000.00 Date January 22, 2021 April 2, 2024 December 31, 2025 Comment Number of health workers deployed for COVID-19 preparedness and response. Value 96.00 4404.00 1602.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Number of monthly assessed (using checklist) PoEs, isolation and quarantine centers Value 0.00 23.00 192.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Number of vaccine laboratory renovated and equipped. Value 0.00 32.00 1.00 Date January 14, 2021 April 2, 2024 December 31, 2025 Comment Number of communication trainings conducted Value 0.00 390.00 115.00 Date March 2, 2021 April 2, 2024 December 31, 2025 Comment Number of target populations estimated who will be prioritized for access to vaccines stratified by target group (sex-disaggregated) Value 0.00 73918132.00 300000.00 Date January 14, 2021 April 2, 2024 December 31, 2025 Comment Percentage of complaints to the Grievance Redress Mechanism (GRM) satisfactorily addressed within 15 weeks of initial complaint being recorded Value 0.00 88.24 90.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Number of communication material leaflets, posters, job aids, wall chart, banners) distributed Value 0.00 288383.00 20000.00 Date March 2, 2021 April 2, 2024 December 31, 2025 Comment Guidelines, documented procedures and tools for planning and conducting vaccine pharmacovigilance activities (i.e. AEFI reporting, investigation, causality assessment, risk communication and response) Value 0.00 100.00 100.00 Date January 14, 2021 April 2, 2024 December 31, 2025 Comment Percentage of grievances addressed within the time specified in the project implementation manual Value 50.00 88.24 80.00 Date May 13, 2022 April 2, 2024 December 31, 2025 Comment Distribution of female PPE matches daily needs of female workers Value No Yes Yes Date February 22, 2021 April 2, 2024 December 31, 2025 Comment Number of airports and PoEs received PPE supplies for airport communities and land crossing PoEs. Value 0.00 23.00 18.00 Date April 2, 2020 April 2, 2024 December 31, 2025 Comment Percentage of adolescent population vaccinated, which is included in the priority population targets defined in national plan Value 0.00 33.90 80.00 Date April 11, 2022 April 2, 2024 December 31, 2025 Comment Percentage of population receiving a booster, which is included in the population targets defined in the national plan Value 0.00 8.50 70.00 Date April 11, 2022 April 2, 2024 December 31, 2025 Comment Vaccine stock management tools and operating procedures updated to reflect the needs for deployment and management of COVID-19 vaccines) Value 0.00 3.00 2.00 Date January 14, 2021 April 2, 2024 December 31, 2025 Comment Dry storage and cold chain capacity assessed with regards to the COVID-19 vaccines Value 0.00 3.00 1.00 Date January 14, 2021 April 2, 2024 December 31, 2025 Comment